Cyano- and Ketone-Containing Selenoesters as Multi-Target Compounds against Resistant Cancers

Cancers (Basel). 2021 Sep 11;13(18):4563. doi: 10.3390/cancers13184563.

Abstract

Fifteen selenocompounds, comprising of eight ketone-containing selenoesters (K1-K8, also known as oxoselenoesters) and seven cyano-containing selenoesters (N1-N7, known also as cyanoselenoesters), have been designed, synthesized, and evaluated as novel anticancer agents. These compounds are derivatives of previously reported active selenoesters and were prepared following a three-step one-pot synthetic route. The following evaluations were performed in their biological assessment: cytotoxicity determination, selectivity towards cancer cells in respect to non-cancer cells, checkerboard combination assay, ABCB1 inhibition and inhibition of ABCB1 ATPase activity, apoptosis induction, and wound healing assay. As key results, all the compounds showed cytotoxicity against cancer cells at low micromolar concentrations, with cyanoselenoesters being strongly selective. All of the oxoselenoesters, except K4, were potent ABCB1 inhibitors, and two of them, namely K5 and K6, enhanced the activity of doxorubicin in a synergistic manner. The majority of these ketone derivatives modulated the ATPase activity, showed wound healing activity, and induced apoptosis, with K3 being the most potent, with a potency close to that of the reference compound. To summarize, these novel derivatives have promising multi-target activity, and are worthy to be studied more in-depth in future works to gain a greater understanding of their potential applications against cancer.

Keywords: ABCB1; apoptosis; cancer; efflux pump; multidrug resistance; selenium.